Lucid Diagnostics (LUCD) Aandelenoverzicht
Lucid Diagnostics Inc. is een commercieel bedrijf in medische diagnostiektechnologie in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
LUCD Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
IN
Community Contributor
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.
View narrativeUS$5
FV
78.6% ondergewaardeerd intrinsieke korting89
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Lucid Diagnostics Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.07 |
| 52 Week Hoogtepunt | US$1.63 |
| 52 Week Laag | US$0.90 |
| Bèta | 1.07 |
| 1 maand verandering | 10.63% |
| 3 maanden verandering | -5.31% |
| 1 Jaar Verandering | 3.88% |
| 3 jaar verandering | -23.02% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -90.90% |
Recent nieuws en updates
Narratiefupdate • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Narratiefupdate • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.Recent updates
Narratiefupdate • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Narratiefupdate • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.
Narratiefupdate • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.Narratiefupdate • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
Nieuw narratief • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Narratiefupdate • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.Narratiefupdate • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Narratiefupdate • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).Narratiefupdate • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).Narratiefupdate • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking AlphaNarratiefupdate • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).Narratiefupdate • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.Analyseartikel • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nieuw narratief • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.Analyseartikel • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.Analyseartikel • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendement voor aandeelhouders
| LUCD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -0.9% | 2.2% | 1.6% |
| 1Y | 3.9% | -19.0% | 18.6% |
Rendement versus industrie: LUCD overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -19 % opleverde.
Rendement versus markt: LUCD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 18.6 % opleverde.
Prijsvolatiliteit
| LUCD volatility | |
|---|---|
| LUCD Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: LUCD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van LUCD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2018 | 82 | Lishan Aklog | www.luciddx.com |
Lucid Diagnostics Inc. is een commercieel bedrijf in medische diagnostiektechnologie in de Verenigde Staten. Het bedrijf richt zich op patiënten met gastro-oesofageale refluxziekte (GERD) die risico lopen op het ontwikkelen van slokdarmprecarcinoom en slokdarmkanker, voornamelijk het zeer dodelijke slokdarmadenocarcinoom. Het vlaggenschipproduct van het bedrijf, de EsoGuard Esophageal DNA Test uitgevoerd op monsters verzameld met de EsoCheck Esophageal Cell collectie apparaat, een testinstrument met als doel het voorkomen van EAC sterfgevallen door middel van vroege detectie van slokdarm precancer in risicopatiënten GERD.
Lucid Diagnostics Inc. Samenvatting
| LUCD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$204.13m |
| Inkomsten(TTM) | -US$58.18m |
| Inkomsten(TTM) | US$5.13m |
39.8x
P/S-verhouding-3.5x
Koers/WinstverhoudingIs LUCD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LUCD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$5.13m |
| Kosten van inkomsten | US$6.74m |
| Brutowinst | -US$1.61m |
| Overige uitgaven | US$56.57m |
| Inkomsten | -US$58.18m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.30 |
| Brutomarge | -31.36% |
| Nettowinstmarge | -1,133.21% |
| Schuld/Eigen Vermogen Verhouding | 630.0% |
Hoe presteerde LUCD op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/05 07:59 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Lucid Diagnostics Inc. wordt gevolgd door 5 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |